Fulcrum Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis
Fulcrum Therapeutics, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Fulcrum's pociredir is on track toward a 2026 registration-enabling trial with analyst price targets of $25, suggesting significant value upside for investors betting on sickle cell disease market opportunity.
What is Fulcrum Therapeutics, Inc.'s industry? Fulcrum Therapeutics, Inc. (fulcrumtx.com) operates in Biopharmaceuticals - Rare Diseases & Hematology. AskCyborg classifies Fulcrum Therapeutics, Inc. under Biopharmaceuticals - Rare Diseases & Hematology in its company registry.
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company developing small molecules to improve the lives of patients with genetically defined diseases in areas of high unmet medical need. The company's lead ...
Cyborg Score thesis
Fulcrum's pociredir is on track toward a 2026 registration-enabling trial with analyst price targets of $25, suggesting...
Read the full analyst-debate transcript →Get the Latest Fulcrum Therapeutics, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeFulcrum Therapeutics, Inc. Overview
Pro stress-test →Fulcrum Therapeutics is a clinical-stage biopharmaceutical company developing small molecules to improve the lives of patients with genetically defined diseases in areas of high unmet medical need. The company's lead candidate is pociredir, an oral small molecule designed to treat sickle cell disease and beta-thalassemia through fetal hemoglobin induction.
Strategic Profile
Pro stress-test →Pociredir showed rapid, robust, clinically relevant response with mean fetal hemoglobin increasing 12.2% at Week 12, with 58% of patients achieving HbF levels ≥20% and 58% reporting zero vaso-occlusive crises. Fulcrum plans to initiate a potential registration-enabling trial in the second half of 2026, pending FDA feedback.
Competitive Landscape
Pro stress-test →Pociredir faces competition from several approved therapies and ongoing clinical trials for sickle cell disease, including gene therapies and small molecule treatments. The company's proprietary EED inhibitor approach targeting fetal hemoglobin induction offers a differentiated oral mechanism compared to complex gene therapy alternatives.
Industry Context
Fulcrum Therapeutics, Inc. operates in Biopharmaceuticals - Rare Diseases & Hematology.
Key facts
Headquarters: Cambridge, Massachusetts, US · Market cap: $773M